Efficacy and safety of nab-paclitaxel or combined nab-paclitaxel and immune checkpoint inhibitors in relapsed small-cell lung cancer

Background: Most patients with small-cell lung cancer (SCLC) experience disease progression after first-line chemotherapy. Notably, nab-paclitaxel monotherapy has antitumor activity in relapsed SCLC. Objective: This study evaluated the efficacy and safety of combined of nab-paclitaxel and immune che...

Full description

Bibliographic Details
Main Authors: Rui Wan, Yanrong Guo, Xuezhi Hao, Zhijie Wang, Jianchun Duan, Jie Wang
Format: Article
Language:English
Published: SAGE Publishing 2023-06-01
Series:Therapeutic Advances in Medical Oncology
Online Access:https://doi.org/10.1177/17588359231179315